Targacept, Inc. Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Alzheimer’s Disease

WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its strategic collaborator AstraZeneca has initiated a Phase IIb clinical trial of AZD3480 (TC-1734) in Alzheimer’s disease. AZD3480, Targacept’s lead product candidate, acts selectively on neuronal nicotinic receptors and has been evaluated in 12 clinical trials in approximately 540 subjects. In a previous Phase IIb clinical trial conducted by Targacept in age associated memory impairment, AZD3480 achieved statistically significant results on all of the primary endpoints, demonstrating cognitive enhancing effects in memory-impaired older adults.

MORE ON THIS TOPIC